Zoetis Beats Q3 Estimates and Raises Guidance, Yet Shares Slide 6% on Pet-Spending Caution
ZTS sits 21% above its 52-week low of $68.77.
Summary
Zoetis beat on both lines: adjusted EPS of $1.75 versus $1.51 consensus and sales of $2.391 billion versus $2.304 billion expected. It also raised FY2026 adjusted EPS guidance to $6.25-$6.35 from $6.15-$6.25 and lifted the sales range to $9.22 billion-$9.320 billion. The problem is the mix. U.S. revenue fell 6% as companion animal dropped 8% on price sensitivity, dermatology competition and generic Convenia and Cerenia, while livestock grew 5%. Management said it will not assume any recovery in the macro environment or pet-owner spending for 2027, and shares fell 6.10% to $83.76 Thursday. The guidance raise is real but the top end of the sales range still sits below the $9.326 billion Street estimate, so the market is treating this as a demand story, not an earnings beat.
At the time of this announcement, ZTS was trading at $83.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $34.4B. The 52-week trading range was $68.77 to $132.49. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.